Gevokizumab is a recombinant humanized anti-IL-1β antibody, that modulates IL-1β bioactivity by reducing the affinity for its IL-1RI:IL-1RAcP signaling complex [61]: it has recently been evaluated in BD patients with refractory uveitis. This evidence concerns the gene IL1B and Behcet disease.